35 Followers on Owler
OverviewCompetitorsFundingNews & Insights

Promentis Competitors or Alternatives

Promentis's top competitors include Cerecin, Adamas and Alexza.

Unlock 19 more competitors →

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

  • FUNDING

    REVENUE

  • EMPLOYEES

    FUNDING

  • REVENUE

  • CEO RATING

  • EMPLOYEES

  • FUNDING

  • REVENUE

Promentis's company profile

Klaus Veitinger

CEO

76/100
25 - 100
$63M
$5M - 25M
  • $63M
    $5M - 25M
  • 25 - 100
    $63M
  • $5M - 25M
  • 76/100
  • 25 - 100
  • $63M
  • $5M - 25M
View ProfileView
1
Promentis's Competitor - Cerecin logo

Charles Stacey

President & CEO

84/100
100 - 250
$259.3M
$25M - 100M
  • $259.3M
    $25M - 100M
  • 100 - 250
    $259.3M
  • $25M - 100M
  • 84/100
  • 100 - 250
  • $259.3M
  • $25M - 100M
View ProfileView
2
Promentis's Competitor - Adamas logo

CEO

- -
100 - 250
$88M
$25M - 100M
  • $88M
    $25M - 100M
  • 100 - 250
    $88M
  • $25M - 100M
  • - -
  • 100 - 250
  • $88M
  • $25M - 100M
View ProfileView
3
Promentis's Competitor - Alexza logo

Tatjana Naranda

President

72/100
25 - 100
$222.9M
$5M - 25M
  • $222.9M
    $5M - 25M
  • 25 - 100
    $222.9M
  • $5M - 25M
  • 72/100
  • 25 - 100
  • $222.9M
  • $5M - 25M
View ProfileView
4
Promentis's Competitor - Minerva Neurosciences logo

Remy Luthringer

CEO

96/100
9
$124.3M
$41.2M
  • $124.3M
    $41.2M
  • 9
    $124.3M
  • $41.2M
  • 96/100
  • 9
  • $124.3M
  • $41.2M
View ProfileView
5
Promentis's Competitor - Alzheon logo

Martin Tolar

President & CEO

84/100
25 - 100
$372.3M
$5M - 25M
  • $372.3M
    $5M - 25M
  • 25 - 100
    $372.3M
  • $5M - 25M
  • 84/100
  • 25 - 100
  • $372.3M
  • $5M - 25M
View ProfileView
Promentis' top 22 competitors are Cerecin, Adamas, Alexza, Neurona, Minerva Neurosciences, Alzheon, Acceleron, TauRx, Alzamend, Avanir, Austrianova, Supernus, Saniona, Bionomics, Hummingbird Bioscience, Pfizer, PRA International, Purdue Pharma, Edison Pharmaceuticals, Process Group Pty. Ltd., Naurex and Abbott. Together they have raised over 4.4B between their estimated 205.7K employees. Promentis's revenue is the ranked 17th among it's top 10 competitors. The top 10 competitors average 5B. Promentis has 40 employees and is ranked 17th among it's top 10 competitors. The top 10 competitors average 8,944.

Promentis VS Cerecin

Cerecin is Promentis's #1 competitor. Cerecin's headquarters is in Singapore, Central Singapore, and was founded in 2001. Like Promentis, Cerecin also works within the Biotechnology sector. Cerecin generates 1,134% of Promentis's revenue.

Promentis VS Adamas

Adamas is one of Promentis's top rivals. Adamas was founded in Emeryville, California} in 2002. Adamas operates in the Pharmaceuticals industry. Compared to Promentis, Adamas generates $69.5M more revenue.

Promentis VS Alexza

Alexza is one of Promentis's top competitors. Alexza is a Private company that was founded in 2000 in Mountain View, California. Alexza is in the Pharmaceuticals industry. Compared to Promentis, Alexza has 40 more employees.

Looking for similar companies to Promentis?

Similar Companies

Biotechnology companies in Milwaukee

See 18 companies 
Pharmaceuticals companies in Milwaukee Metropolitan Area

See 34 companies 
Pharmaceuticals & Biotechnology companies in Milwaukee

See 23 companies 
Biotechnology companies in Milwaukee Metropolitan Area

See 48 companies 
Pharmaceuticals & Biotechnology companies in Milwaukee Metropolitan Area

See 69 companies 
Pharmaceuticals companies in Wisconsin

See 87 companies 
Biotechnology companies in Wisconsin

See 142 companies 
Pharmaceuticals & Biotechnology companies in Wisconsin

See 206 companies 
Pharmaceuticals companies with revenue in $5.0-25M range

See 2,472 companies 

Advanced Search

PRO

Discover new companies using five search parameters, including sector, location, public/private company status, employee count, and annual revenue.

Discover new companies using five search parameters.

Trending News for Promentis and Promentis's Competitors

April 28, 2025Applied Clinical Trials
In the pivotal CREST clinical trial, sasanlimab in combination with Bacillus Calmette-Guérin met the primary endpoint of event-free survival....
April 28, 2025Seeking Alpha
April 29, 2025CNBC
Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time."...
April 29, 2025Benzinga
read more...
April 29, 2025Citybizlist
NASHVILLE, Tenn. & PRINCETON, N.J.-(BUSINESS WIRE)-Leading growth equity firm Edison Partners today announced its exit from MoneyLion (NYSE: ML), follo...
April 29, 2025Pharmabiz
Pfizer Inc. announced results from the pivotal phase 3 CREST trial of sasanlimab, an investigational anti─PD─1 monoclonal antibody (mAb), in combinatio...
April 28, 2025BioSpace
Pfizer's sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistenc...
April 28, 2025Businessinsider
Bullish option flow detected in Pfizer ( PFE ) with 45,740 calls trading, 1.0x expected, and implied vol increasing over 1 point to 30.86%. 5/2 weekly ...

Frequently Asked Questions about Promentis

  1. Who are Promentis's top competitors?

    Promentis's top 3 competitors are Cerecin, Adamas, Alexza.

  2. Who is similar to Promentis?

    Cerecin is the most similar to Promentis. Adamas and Alexza are also similar to Promentis.

  1. Are Promentis and Cerecin competitors?

    Yes, Cerecin is one of Promentis’s top competitors.